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Abstract
Background: Stillbirth remains a major concern across the globe and in some high-resource countries, such as the
UK; efforts to reduce the rate have achieved only modest reductions. One third of stillborn babies are small for
gestational age (SGA), and these pregnancies are also at risk of neonatal adverse outcomes and lifelong health
problems, especially when delivered preterm. Current UK clinical guidance advocates regular monitoring and early
term delivery of the SGA fetus; however, the most appropriate regimen for surveillance of these babies remains
unclear and often leads to increased intervention for a large number of these women. This pilot trial will determine
the feasibility of a large-scale trial refining the risk of adverse pregnancy outcome in SGA pregnancies using
biomarkers of placental function sFlt-1/PlGF, identifying and intervening in only those deemed at highest risk of
stillbirth.
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Methods: PLANES is a randomised controlled feasibility study of women with an SGA fetus that will be conducted
at two tertiary care hospitals in the UK. Once identified on ultrasound, women will be randomised into two groups
in a 3:1 ratio in favour of sFlt-1/PlGF ratio led management vs standard care. Women with an SGA fetus and a
normal sFlt-1/PlGF ratio will have a repeat ultrasound and sFlt-1/PlGF ratio every 2 weeks with planned birth
delayed until 40 weeks. In those women with an SGA fetus and an abnormal sFlt-1/PlGF ratio, we will offer birth
from 37 weeks or sooner if there are other concerning features on ultrasound. Women assigned to standard care
will have an sFlt-1/PlGF ratio taken, but the results will be concealed from the clinical team, and the woman’s
pregnancy will be managed as per the local NHS hospital policy. This integrated mixed method study will also
involve a health economic analysis and a perspective work package exploring trial feasibility through interviews and
questionnaires with participants, their partners, and clinicians.
Discussion: Our aim is to determine feasibility through the assessment of our ability to recruit and retain
participants to the study. Results from this pilot study will inform the design of a future large randomised
controlled trial that will be adequately powered for adverse pregnancy outcome. Such a study would provide the
evidence needed to guide future management of the SGA fetus.
Trial registration: ISRCTN58254381. Registered on 4 July 2019
Keywords: Fetal growth restriction (FGR), Intrauterine growth restriction, Small for gestational age (SGA), Placenta,
Placental growth factor, Soluble fms-like tyrosine kinase
Background
The stillbirth rate within the United Kingdom (UK) re-
mains one of the highest in high-resource countries
(3.87 per 1000 births) [1], but stillbirths remain rare at
term (2.0 per 1000 births) [2]. Historically strategies to
prevent stillbirth have focused on the identification of
risk factors in early pregnancy [3–9]. However, risk fac-
tors present at booking predict less than 20% of all still-
births [8]. Furthermore, 33% of stillbirths occur after 36
+ 0 weeks, 85% prior to labour with the cause of death
unknown in 39% [8]. A third of all stillbirths however
are small for gestational age (SGA), and therefore, tar-
geted identification and intervention on the small fetus
has become an attractive surrogate strategy to prevent
subsequent stillbirth [8]. Even when identified ante-
natally, SGA fetuses are at a significantly higher risk of
stillbirth (odds ratio 7.0, 95% confidence interval 3.3–
15.1) [10–12], neonatal adverse outcome [13] and poten-
tial life-long health risks [14, 15].
The standard approach advocated by the National In-
stitute for Health and Care Excellence (NICE) for all
pregnant women in the UK to identify the SGA fetus re-
lies upon serial measurement of the maternal abdomen
with a tape measure from 24 weeks to generate the sym-
physial fundal height (SFH) [16]. SGA is suspected when
the SFH measurement is < 10th centile or there is static
growth over two measurements. SFH measurement in
isolation has a sensitivity of 30–40% [17, 18] and with
no randomised controlled studies of its effectiveness
[19]. Therefore, confirmatory ultrasound assessment is
required, with SGA commonly defined as an estimated
fetal weight (EFW) < 10th centile [4, 17, 20]. However,
the increase in detection of SGA with ultrasound is
limited, with up to 41% of SGA fetuses remaining un-
diagnosed and a false positive rate of up to 20% [18].
The Royal College of Obstetricians and Gynaecologists
(RCOG) has produced guidance for the management of
the SGA fetus [17], but the Cochrane Collaboration
acknowledges that the most appropriate regimen for
antenatal surveillance is unclear [19]. This guidance ad-
vocates that the SGA fetus should have growth assessed
with ultrasound every 2 weeks with additional fetal blood
flow (Doppler) assessments. Timing of delivery is based
upon deterioration in fetal growth or fetoplacental Dop-
pler (< 37 weeks) or when the pregnancy reaches 37 + 0
weeks’ gestation even if all other factors are normal [17].
Therefore, the UK National Health Service (NHS) cur-
rently has a system for the management of the SGA
fetus and prevention of stillbirth based upon SFH and
confirmatory ultrasound with delivery from 37 + 0
weeks. This ‘one size fits all’ approach maintains a safety
margin to prevent stillbirth but leads to an increase in
interventions, such as induction of labour (IOL) [21].
IOL rates for SGA are increasing (3.0% in 2012 to 10.7%
in 2016) with up to 40% of all labours now induced [22].
Our recent survey of UK obstetric units demonstrates
that this is a UK-wide phenomenon with mean induc-
tion rates at 30% (range 17–46%) [22], with 67% of re-
sponders observing an increase over 5 years and 90%
stating that in their opinion management of SGA had
been a factor. This increased intervention and delivery
of SGA fetuses at a late preterm or early term gestation,
whilst well intentioned is not without concern. There is
a substantial body of evidence showing that being born
< 39 weeks has an impact upon a child’s cognitive devel-
opment and later academic achievement [23–26].
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Furthermore, whilst overall numbers of affected children
are low, the term SGA fetus has a cerebral palsy risk 5–
7 times greater than normal birth weight babies [27, 28].
There is also an impact on women’s choice as to place
and mode of birth, especially when in general the risk of
stillbirth is low [29] with intervention potentially not re-
quired for all SGA fetuses.
Rationale for study population
The desire to reduce stillbirth is powerful, but due to
the relative infrequency of this outcome, it currently
leads to increased intervention for a large number of
women, which impacts upon a women’s choice and in-
creases the burden on the health care system. However,
most importantly whilst small gains have been made in
stillbirth reduction in the UK, the goal of significantly
reducing stillbirth remains distant. Not all national
guidelines are as prescriptive on the management of
SGA, recently reviewed by McCowan et al. [30]. Canad-
ian [31] guidance suggests close monitoring of the fetal
condition with ultrasound after 37 weeks but with no de-
fined time to deliver. Irish [32], US, and New Zealand
guidance [33] is also more flexible suggesting that in the
presence of normal Doppler studies the SGA fetus can
be left until 38–39 or 40 weeks respectively. Much of
this evidence for lack of harm from delaying delivery
comes from the DIGITAT study that showed no adverse
effects from induction of labour vs delayed delivery [34],
though this study was underpowered to offer unequivo-
cal evidence regarding perinatal mortality or severe mor-
bidity. Recently, some reaction against early delivery for
SGA in the absence of other risk factors has been ob-
served with a recent UK study deferring delivery until
40 weeks if fetal assessment was normal [35]. However,
in this study there was a single stillbirth in the deferred
cohort possibly suggesting that additional reassurance of
fetal wellbeing is required.
We suggest a potential ‘middle ground’ would be to re-
fine the risk of adverse pregnancy outcome in SGA preg-
nancies with biomarkers of placental function, namely the
sFlt-1/PlGF ratio. We feel that this may help clinicians to
differentiate the fetus that is constitutionally small from
that which has a reduced growth velocity due to placental
failure. Identifying the group at highest risk of stillbirth
would reduce the number of interventions performed and
reduce the number of babies delivered early whilst main-
taining a safety margin to prevent stillbirth. This would
represent a more detailed monitoring system than any
other nation currently advocates. It would also align with
the recent Saving Babies’ Lives Care Bundle, which advo-
cates individualised risk assessments of SGA pregnancies
and deferring delivery to 39 weeks in those pregnancies
with no high-risk features [36].
Justification for intervention and biomarkers
The use of biomarkers to identify the fetus at risk of
stillbirth has been highlighted as a priority by the RCOG
[17] and the James Lind Alliance [37]. However, their
low predictive accuracy in the first trimester has limited
their use as a screening tool [3]. Recent advances in our
understanding of which biomarkers are clinically rele-
vant in late pregnancy has demonstrated that identifica-
tion of placental disease potentially predisposing to
stillbirth is possible [38]. Principal among the bio-
markers currently available is placental growth factor
(PlGF). This protein is produced by the placenta and
identifiable in maternal blood from 12 weeks [39]. Two
commercially available platforms which measure PlGF
(Alere®) [40] or PlGF relative to sFlt-1 (sFlt-1/PlGF ratio)
(Roche®) [41] have been endorsed by NICE for the inves-
tigation of hypertension in pregnancy [42]. Whilst the
majority of studies have focused on the ability of these
tests to predict preeclampsia, there is a significant
amount of information on their ability to predict still-
birth and SGA. Abnormally low levels of PlGF in mater-
nal plasma have been linked to preeclampsia [40, 43,
44], SGA [45, 46], and stillbirth [40, 47]. Furthermore,
an abnormal PlGF appears to more than double adverse
pregnancy outcome [48] and is associated with critical
fetal growth restriction [49–53]. In a cohort of SGA fe-
tuses, low PlGF was associated with preterm delivery,
stillbirth, birth weight < 3rd centile, Apgar < 7 at 5 min,
NICU admission and placental pathology [40, 54, 55].
Women with the lowest PlGF values were in addition
much more likely to have a growth-restricted fetus and
abnormal Dopplers [40, 47]. In all published studies to
date, very few fetuses have been stillborn following a
normal PlGF result [40, 47, 53, 56, 57]. The ratio of PlGF
to soluble FMS-like tyrosine kinase-1 (sFlt-1), which
binds PlGF in the circulation, is increased in preeclamp-
sia [41], fetal growth restriction [58] and stillbirth [59].
An abnormal sFlt-1/PlGF ratio of > 38 is associated with
an increased risk of SGA (21% vs 7%) [60]. The sFlt-1/
PlGF ratio appears to be equally useful in determining
outcome with almost no stillbirths when the ratio is nor-
mal [41, 56, 57, 59, 60] (Table 1). A recent Cochrane
Diagnostic Test Accuracy Review on the effectiveness of
biomarkers to predict stillbirth [61] confirms that abnor-
mal PlGF or sFlt-1/PlGF ratio has a diagnostic odds ratio
of 49.2 for subsequent stillbirth. Therefore, PlGF or sFlt-
1/PlGF ratio appears to be effective in identifying the
fetus that is SGA and more importantly, those fetuses
that go on to be stillborn.
Objective
The PLANES study (Placental Growth Factor Led Man-
agement of the Small for Gestational Age Fetus) has the
following overall objectives: (1) to assess the feasibility of
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delivering sFlt-1/PlGF ratio led management of women
with an SGA fetus, (2) to assess the acceptability of such
an approach to women and clinicians, and (3) to explore
the feasibility/acceptability of the study design.
Results from this feasibility study will inform the de-
sign of a future large randomised controlled trial (RCT)
powered for adverse pregnancy outcome.
Methods/design
The PLANES study is a randomised controlled feasibility
study of standard care versus sFlt-1/PlGF ratio led man-
agement of pregnant women with an ultrasound diagno-
sis of an SGA fetus (defined as having an EFW < 10th
percentile for gestation) at 32 + 0 to 37 + 6 weeks’ gesta-
tional age. The 10th centile will be defined by what is
considered to be usual practice for each site; both sites
in the pilot study use the customised GROW chart. This
integrated mixed method study will also involve a health
economic analysis and a perspectives work package ex-
ploring trial feasibility through interviews and question-
naires with randomised patients and their partners, as
well as a clinician focus group and/or questionnaires
and interviews.
Participants
Inclusion criteria are women with a singleton pregnancy,
confirmed SGA fetus (EFW < 10th centile on ultrasound
within preceding 72 h), normal umbilical artery Doppler
(pulsatility index < 95th centile), between 32 + 0 and 37
+ 6 weeks of gestation, maternal age > 16 years old and
able to give written informed consent. Exclusion criteria
are known or suspected structural/chromosomal fetal
abnormalities, either absent or reversed end diastolic
flow in the umbilical artery on Doppler study, and severe
maternal disease requiring urgent delivery. Participation
in the perspectives work package follows the same cri-
teria for participants, with the additional exclusion cri-
teria of women who do not speak English. The flow of
each participant from consent through to follow-up is
shown in Fig. 1.
Intervention
Following randomisation, women will be asked to pro-
vide a blood sample for assessment of sFlt-1/PlGF ratio;
the result of which will be revealed (biomarker led) or
concealed (standard care) from the attending clinical
team.
Within the revealed/biomarker led care group, partici-
pants with a normal sFlt-1/PlGF ratio (≤ 38) will be ad-
vised that their risk of an adverse pregnancy outcome is
low and will be offered delivery at 40 + 0 weeks gesta-
tion. Women will be offered further ultrasound and sFlt-
1/PlGF ratios every 2 weeks, to ensure that they do not
become high risk, with the care pathway adjusted if ne-
cessary (see Fig. 1). Participants with an abnormal sFlt-
1/PlGF ratio (> 38) will be advised to attend for detailed
ultrasound assessment by a fetal medicine expert within
72 h of the abnormal result being known. This assess-
ment will involve fetal biometry and Doppler of the um-
bilical artery (UA), middle cerebral artery (MCA), and
ductus venosus (DV). If Doppler studies are normal,
then, delivery will be advised from 37 + 0 weeks [17]. If
there is evidence of critical fetal compromise (absent
end diastolic flow in the UA or absent a-wave in the
DV), then, delivery will be performed as soon as feasible.
If fetal Doppler studies are borderline (brain sparing
(MCA pulsatility index < 5th centile) or increased resist-
ance in UA or DV (pulsatility index > 95th centile)), the
Doppler will be repeated every 72 h, and delivery will be
offered between 36 + 0 and 37 + 0 weeks.
Women assigned to the concealed/standard care path-
way will have an sFlt-1/PlGF ratio taken, but the result
will be concealed from the clinical team with their preg-
nancy being managed as per the local NHS guideline
with delivery from 37 + 0 weeks.
In all cases, women will receive cCTG on the same
day as ultrasound assessment and a minimum of twice
weekly. If at any point cCTG demonstrates a short-term
variability (STV) < 3.0 ms, then, delivery should be
planned [62]. If at any point the attending clinical team
feels the need to deviate from a care pathway, they will
Table 1 Stillbirths by normal and abnormal PlGF and sFlt-1/PlGF ratio








Chappell et al. [40] 2013 0 7 - -
Benton et al. [53] 2016 1 6 - -
Zeisler et al. [41] 2016 - - 1 3
Sovio et al. [59] 2017 - - 0 0
Sharp et al. [47] 2018 0 1 - -
Sharp et al. [56] 2018 0 35 0 35
Navaratnam et al. [57] 2017 0 1 0 1
Total 1 50 1 39
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also be able to do so, with outcomes recorded on an
intention-to-treat basis. Women who prefer not to be
randomised into the PLANES study will be offered the
opportunity to give blood for a sFlt-1/PlGF ratio test
with the result being concealed and not used to guide
clinical management.
Outcome measures
This study will assess the feasibility of using a blood bio-
marker, sFlt-1/PlGF ratio, to safely refine the care path-
way for the management of women with an SGA fetus
from 32 weeks of pregnancy. Post hoc analysis of sFlt-1
and PlGF individually will also be conducted. The out-
comes for the study have been separated into those that
determine the feasibility of a definitive trial and those
that address whether the intervention might have an ef-
fect on neonatal outcome or healthcare costs. Our group
has had previous successful experience employing this
approach in the ReMIT-2 study [63].
The feasibility outcomes are as follows: number of eli-
gible women at each site, the number of women re-
cruited, the number of women randomised, the number
of women not compliant with the intervention and the
reasons for this, reasons for not participating (patients
may still consent to the perspectives work package who
do not wish to participate in the main study) and num-
ber of women lost to follow-up. Women’s and birth
partner’s views on the approach to recruitment, includ-
ing consent, decision-making and length and content of
trial information materials and views on the sFlt-1/PlGF
test will also be gathered in the perspectives work pack-
age. Clinicians’ views on the acceptability of a future trial
including potential barriers to recruitment, consent deci-
sions, trial procedures and clinician training needs via
questionnaires and a focus group or interview will be
collected.
The proof of concept outcomes for mother includes
the following: gestation and frequency of induction of
labour or planned caesarean, frequency of maternal
Fig. 1 PLANES patient flow diagram
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hypertensive disorders, intensive care admission or ma-
ternal death prior to discharge. The proof of concept
outcomes for the baby include stillbirth, neonatal death,
Apgar score at 5 min < 7, umbilical artery pH < 7.05,
birthweight < 10th centile, admission to neonatal unit
and length of stay, use of therapeutic cooling, length of
stay in hospital and duration of respiratory support.
Sample size and recruitment
As a feasibility study, success will be determined on the
acceptability of the management approach for women
and clinicians. Participants will be recruited directly
from the fetal medicine, antenatal clinic or maternity as-
sessment units at the nominated research sites. It is pro-
posed that the study should expect to recruit in the
region of 100 participants across two sites over a 12
month period. This is a pragmatic figure which is based
on the typical number of SGA patients seen per annum
in large consultant-led NHS units within the UK.
Participants will remain in the study for a maximum
of 8 weeks (from 32 + 0 weeks [earliest point of eligibil-
ity] to estimated due date (EDD)). The study will end
when the last recruited woman/baby is discharged from
hospital after birth (up to age 1 month uncorrected) or
the baby has reached their EDD.
Enrolment and consent
Prior to taking part in the study, all women will have
confirmation of their SGA status completed by their at-
tending clinician based on an ultrasound scan performed
within the preceding 72 h. Once a potential participant
has been identified (all eligibility criteria met), they will
be invited to take part in the study and a member of the
clinical research team at site will discuss this with them.
At this point, the woman and partner will receive writ-
ten (PLANES patient information sheet (PIS)) and verbal
information on the PLANES study, as well as an oppor-
tunity to ask questions and take any additional time re-
quired to consider taking part in the study. All potential
participants will be given a unique screening ID that will
subsequently be used to detail the reasons for the con-
tinuation or discontinuation at the screening stage. Par-
ticipants willing to proceed will be asked to sign the
study-specific informed consent form (ICF), and once
written informed consent has been provided, partici-
pants will be registered onto the study and randomised
by the research midwife/clinician at site.
The PLANES PIS will also include information regard-
ing taking part in the perspective work package. If women
are happy to take part in this, they will be asked to
complete the relevant sections of the study ICF. Women
who decline to take part in the main study will also be
asked if they would like to take part in this perspective
work package, and these participants will be expected to
complete the standard participant ICF, initialling only
those boxes relevant to the perspective study.
The research team are conscious that women may not
feel that they should deviate from ‘normal’ NHS care
despite the more detailed assessments of fetal wellbeing
PLANES have set in place. In order to increase the abil-
ity of this study to inform a future RCT powered to pre-
vent stillbirth, we will ask women who decline to be
randomised whether they would consent to a single sFlt-
1/PlGF ratio being taken and stored for processing only
after the study has ended. In this way, we may still gain
valuable information about the ability of this test to pre-
dict clinically relevant pregnancy outcomes even if
women do not wish to be randomised.
The critical data in the PLANES study is derived from
blood samples. Refusal to give the crucial blood sample
at randomisation would result in significant compromise
to the study. Therefore, any participant who does not
provide this sample would need to be withdrawn from
the study. Participants can refuse any further subsequent
blood sample and remain in the study under the
intention-to-treat principle.
Randomisation
As there is greater value in the outcomes and opinions of
those women undergoing the intervention, participants
will be randomised to receive revealed (biomarker led) or
concealed pathways in a ratio of 3:1. Patients will be ran-
domised by authorised site staff using an electronic ran-
domisation system, accessed by delegated site staff using a
secured password-protected website. The randomisation
code list will be generated on the basis of randomly per-
muted blocks by a Liverpool Clinical Trials Unit (LCTU)
statistician using the ‘ralloc’ command with the software
package STATA. LCTU information security staff at the
University of Liverpool will be responsible for designing
and supporting the PLANES randomisation programme.
It is not possible to blind the participant, or their attend-
ing midwife or clinician, to their allocated pathway at ran-
domisation as the sFlt-1/PIGF ratio taken in the
biomarker-led pathway will inform further management.
Trial assessments and procedures
A prerequisite prior to randomisation of the participant
into the PLANES study is a review of the participants
medical and medication history; fetal assessments in-
cluding computerised CTG and fetal ultrasound; and
maternal observations including blood pressure, pulse
and urinalysis. Once informed consent has been ob-
tained, the participant will be asked to provide a blood
sample for assessment of the sFlt-1/PlGF ratio. The par-
ticipant will then be randomised to either the revealed
or concealed pathway. At this time, the patient will also
complete an EQ-5D-5L health questionnaire, and those
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consented to the perspectives work package will under-
take a questionnaire and with additional patient consent
either face-to-face or telephone interviews.
Continuing assessments will vary depending on the
participant’s care pathway within the study; those in the
control/concealed pathway receiving standard care and
Table 2 Schedule of study-related assessments/procedures
Procedure aScreening aBaseline Study visit 1 Study visit 2 Study visit 3 Delivery Postnatal End of study
Global outcomes
Review of medical history X
Review of medication X
Maternal assessment Blood pressure X X X X
Pulse X X X X
Urine dip X X X X
Fetal assessment Ultrasound (growth,






Blood sample collection X X X X
Qualitative: women/partner X X
Qualitative: clinician X
Health economic: EQ-5D-5 L X X
Health economic: CEQ X
Delivery outcomes X
Maternal postnatal outcomes X
Neonatal postnatal outcomes X
End of study outcomes X
bConcealed—standard care pathway
Adverse event reporting X
Collection of standard care outcomes X
cRevealed—normal group pathway
Maternal assessment BP X X X X X
Pulse X X X X X
Urine dip X X X
Fetal assessment Ultrasound (growth,
liquor, and UA Doppler)
X X X
cCTG X X X
Adverse event reporting X X X X X X
Blood sample collection X X X
dRevealed—abnormal group pathway
Maternal assessment BP X X X X X
Pulse X X X X X
Urine dip X X X
Fetal assessment Ultrasound (growth,
liquor and UA Doppler)
X X X
cCTG X X X
MCA and DV Doppler X X X
Adverse event reporting X X X X X X
aFor some participants, the decision to take part in the study may be within 24 h; in such circumstances, baseline assessments/procedures will take place
at randomisation
bParticipants to be managed as per local standard practise
cStudy visits to take place every 2 weeks up to delivery or 40 + 0 wGA
dStudy visits to take place every 72 h up to delivery from 36 + 0 wGA
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assessments on adverse events and standard care, out-
comes will take place at the end of study. Participants
within the revealed/biomarker led pathway will undergo
blood pressure, pulse, urinalysis, computerised CTG and
fetal ultrasound assessment as well as repeat sampling
for sFlt-1/PlGF ratio as detailed below dependent on
previous sFlt-1/PlGF ratio results and Doppler studies.
In all cases, women will receive cCTG on the same day
as ultrasound assessment and a minimum of twice
weekly. Further assessments will take place after delivery
and before discharge from hospital, and this will include
a repeat EQ-5D-5L health questionnaire, childbirth ex-
perience questionnaire and recording of delivery out-
comes, and following this in the postnatal period,
assessments on maternal and neonatal outcomes will be
completed (See Table 2).
Clinicians at site at the end of the study will be asked
to participate in focus groups, and for those who are un-
able to attend, online questionnaires and interviews will
also be undertaken.
Adverse event reporting
All adverse events for this study will be recorded at each
study visit, the condition of each participant monitored
throughout the study until 1 month postnatal. The inter-
vention to which participants are randomised to as part
of this study provides additional care to that which is
usually provided as part of local standard care and there-
fore large numbers of serious adverse events are not an-
ticipated. SAE to be reported are that of intrauterine
fetal death (stillbirth), maternal death and neonatal
death; all of which are also pre-specified outcomes for
the study. Less serious adverse events (preterm delivery,
pre-eclampsia, caesarean section, admission to neonatal
unit) are exempt from immediate safety reporting due to
the anticipation of these in SGA pregnancies—unless a
causal relationship to the study design is suspected.
sFlt-1/PlGF ratio blood tests
The sFlt-1/PlGF ratio will be used to guide intervention
in the study; Roche® has agreed to provide the sFlt-1/
PlGF ratio kits for no cost. Blood samples relating to the
intervention pathway collected at Liverpool Women’s
Hospital and St Mary’s Hospital will be analysed within
the Liverpool Clinical Laboratories at the Royal Liver-
pool and Broadgreen University Hospital NHS Trust
and the Manchester University NHS Foundation Trust,
respectively. Additional samples that will be collected
from both sites will be sent to the Centre for Women’s
Health Research laboratories where they will be proc-
essed and stored until the end of the study.
In order to get the most information possible during
the study period, we will be asking women to allow us to
use the remaining blood taken during PLANES to be
used in other ethically approved research, a process
called ‘gifting’. Since the initial application of the PLAN
ES study, other companies have begun to produce PlGF
biomarker tests (Perkin-Elmer and Quidel), and we will
perform post hoc analysis of blood samples with these
companies to ascertain whether they could be used in
the future management of SGA. Neither of these tests
will however be used to determine clinical care pathway
during the study period.
Data management
Study data will be captured using electronic case report
forms (eCRFs) transcribed to a bespoke study database
with participants identified only by their unique partici-
pant identification number allocated at randomisation. It
will be accessed via a secure webpage by delegated re-
search site staff and is designed and maintained by the
LCTU. All eCRF data entered into the study database
will be centrally monitored by the Centre for Women’s
Health Research to ensure that data collected is consist-
ent with adherence to the study protocol. The database
also includes validation features which will alert the user
to certain inconsistent or missing data on data entry,
and if any problems are identified via automated valid-
ation or central monitoring, a query is raised and
emailed to site. Regular reports will be generated to
identify discrepancies in the data and allow for follow-
up. Electronic and paper screening logs will also be kept
in clinics to record the number of patients declining par-
ticipation and when volunteered the reason given; all of
which will be kept in a secure locked location on NHS
premises.
Statistical analysis
Analysis of study data will take place once all partici-
pants have received the planned follow-up and all data is
available. The likelihood of missing data is small given
the standard procedure in place to manage the study
centrally. Therefore, final analyses will take place on a
complete-case basis with no adjustments made (e.g. mul-
tiple imputation) in the case of missing data.
A statistical analysis plan will be determined and fina-
lised prior to final data lock. As the analyses being car-
ried out are based on feasibility, the details in terms of
the methodology may be altered during the course of
the study. Patients will be summarised on an intention-
to-treat basis retaining all patients irrespective of any
protocol deviations. Further secondary analysis will be
carried out on a per protocol population. Further ana-
lyses may be carried out on planned subgroups (e.g.
those who meet the inclusion criteria for a future study)
as is required. Multivariate data analysis techniques will
be also used to attempt to find natural groupings in the
generated data including hierarchical cluster analysis
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and principle component analysis. As this is an explora-
tory study, no formal levels of significance are set. All
statistics presented will be presented alongside 95% con-
fidence intervals so as to give an indication of the level
of precision only. Continuous data will be summarised
as median, interquartile range (IQR) and ranges, and cat-
egorical data shall be summarised as frequencies of
counts and associated percentages. Quantitative analysis
will involve simple descriptive statistics and the chi-
square test for trend. Data from each method will be
analysed separately then synthesised through the use of
constant comparative analysis.
Perspective work package
The perspective work package will include clinicians in-
volved in PLANES as well as women, and their partners,
who have provided consent to be contacted during en-
rolment into the PLANES study. Questionnaires and in-
terviews will involve women in both the concealed and
revealed pathways as well as those who declined ran-
domisation. This will allow for meaningful exploration
of different experiences on the approach to recruitment
in the PLANES study, consent, decision-making and
length and content of trial information materials. Each
patient and their partner (if applicable) will be provided
with the PLANES questionnaire. The PLANES re-
searcher will make contact with women and their part-
ners (if applicable) to arrange an interview within
approximately 1 month of consent. All interviews will be
conducted using the PLANES women and partner inter-
view topic guide which has been informed by previous
pilot trials within the NHS, and respondent validation
will be used so previously unanticipated topics can be
added as analyses progress [64, 65]. The University of
Liverpool PLANES Qualitative study team will conduct
all focus groups and interviews. Interviews will be con-
ducted until data saturation point; this is anticipated to
be 15–25 interviews and approximately 50 question-
naires (48% response rate).
Clinicians involved in the PLANES study will be sent
an email invitation to participate in a focus group at the
end of the PLANES study recruitment period. The focus
group (approximately 8–10 participants) will incorporate
the use of voting software so that both qualitative and
quantitative data are collected. All focus groups and in-
terviews will be conducted using the clinician focus
group and interview topic guides which will be informed
by interim findings from women and birth partner ques-
tionnaires and interviews. Those unable to attend the
focus group will be invited to participate in an interview
and an online questionnaire.
Thematic analysis of qualitative data from the inter-
views, questionnaires, and focus groups will be assisted
using NVivo 10 qualitative data analysis package and the
SPSS software for statistical analysis. Whilst data will be
analysed thematically, the focus will be modified to fit
with the criterion of catalytic validity, whereby findings
should be relevant to future research and practice (in
particular, insight into trial acceptability and the design
of the potential definitive RCT) [66, 67].
Health economic analyses
By performing sFlt-1/PlGF ratio on women with SGA
babies, we hope to be able to reduce the likelihood of
intervention in those with a normal result, in turn redu-
cing the number of preterm and early term deliveries
and associated neonatal care. In those with abnormal re-
sults, greater recognition of clinical concern and more
detailed assessments may improve the outcomes for
these high-risk pregnancies. All of these outcomes have
important cost implications that would need further,
comprehensive assessment in a larger definitive trial.
The overarching aim of the economic analysis embed-
ded in this study is to assess the feasibility of collecting
relevant information on key economic outcomes. Such
outcomes include health care resource use (e.g. care re-
lated to birth and complications, cost of additional
diagnostic tests) and relevant structured quantitative out-
comes, related to childbirth experience and maternal
health-related quality of life. Childbirth experience will be
captured through the use of the Childbirth Experience
Questionnaire administered shortly after delivery [68, 69].
Quality of life will be collected through the widely used
EuroQol 5D-5 L instrument, which will be administered
before and after delivery [70]. The quality and complete-
ness of the collected data will be assessed, and findings
will inform data collection methods and schedules in the
subsequent RCT.
Trial governance
The PLANES study will have a Trial Management
Group (TMG), Trial Steering Committee (TSC) and an
Independent Safety and Data Monitoring Committee
(ISDMC) to monitor the study progress.
The TMG will be responsible for the day-to-day run-
ning and management of the study and will be com-
prised of the CI and other lead investigators/core study
management staff. The TSC will provide oversight of the
study, concentrating on progress of the study, adherence
to protocol, participant’s safety and consideration of new
information, making recommendations on study path-
way modifications and continuation of the study.
The ISDMC will be responsible for reviewing and
assessing recruitment, interim monitoring of safety and
effectiveness, trial conduct and external data. A sub-
committee will also meet to provide ongoing review on
any maternal, fetal or neonatal deaths reported on the
study as SAEs and to provide ongoing review of AE’s.
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The ISDMC will also provide recommendations to the
TSC concerning continuation of the study.
Discussion
PLANES will assess the ability to modify the care of
women carrying a SGA fetus at late preterm and term
gestations using the placental biomarker sFlt-1/PlGF ra-
tio with the aim of safely delaying delivery to a later
gestation than currently advocated. The PLANES study
will provide data on the acceptability of this manage-
ment to participants and clinicians as well as the cost
implications of the proposed intervention; both of which
are important in determining if a larger RCT is feasible.
The results from this study will be used to inform a fu-
ture large randomised controlled trial investigating the
effectiveness and cost-effectiveness of sFlt-1/PlGF led
management of SGA fetuses, powered for adverse preg-
nancy outcome.
It is evident that more research is needed into the op-
timal management and timing of delivery of an SGA
fetus. The current blanket approach by the RCOG [17]
and many other national guidelines may reduce the risk
of term stillbirth; however, this comes at the detriment
of a large proportion of SGA pregnancies undergoing
early term deliveries who may not have needed this
intervention and may increase the long-term risks from
earlier delivery which could have been avoided.
Biomarkers for placental function may hold the key to
identifying those pregnancies truly at risk of adverse out-
comes, allowing for individualised care and reduction in
intervention; however, at present, there is insufficient
evidence to make a judgement regarding the efficacy of
this approach [71]. Initial studies of the implementation
of sFlt-1/PlGF ratio suggest that using biomarkers to de-
termine requirement for or the timing of intervention is
feasible [72]. More research and intervention trials in
this area will not only address the priorities identified in
the recent Saving Babies’ Lives Care Bundle but will help
further develop guidance on the management of the
SGA fetus [36].
Trial status
Trial registration: ISRCTN58254381. Protocol Version
2.0 7 August 2019. Recruitment due to commence June
2020
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